Barbara J. Mason
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Barbara J. Mason has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Charles J. Heyser
Franklin and Marshall College
5 shared publications Susan Quello
Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California
4 shared publicationsVivian Goodell
The Scripps Research Institute, La Jolla, California, USA
4 shared publicationsAdnan Begovic
Pearson Center for Alcohol and Addiction Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA
3 shared publicationsFarhad Shadan
Pearson Center for Alcohol and Addiction Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA
3 shared publications- Natania A. Crane
Department of Psychiatry, University of Illinois Chicago, United States of America
3 shared publications
Latest Publications
- Open Access
- 26 July 2024
- Published by Elsevier in Biological Psychiatry Global Open Science
- Vol. 4 (6) , 100368
The Predictive Value of Plasma Bioactive Lipids on Craving in Human Volunteers With Alcohol Use Disorder
- 26 July 2024
- Published by Elsevier in Biological Psychiatry Global Open Science
- Vol. 4 (6) , 100368
Open AccessThe Predictive Value of Plasma Bioactive Lipids on Craving in Human Volunteers With Alcohol Use Disorder
- Open Access
- 5 January 2024
- Published by Elsevier in Neurobiology of Stress
- Vol. 29, 100604
A reverse translational study of PPAR-α agonist efficacy in human and rodent models relevant to alcohol use disorder
- 5 January 2024
- Published by Elsevier in Neurobiology of Stress
- Vol. 29, 100604
Open AccessA reverse translational study of PPAR-α agonist efficacy in human and rodent models relevant to alcohol use disorder
- 1 May 2021
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 178 (5) , 375-377
Medications to Treat Alcohol Use Disorder: Targeting the Dark Side
- 1 May 2021
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 178 (5) , 375-377
Medications to Treat Alcohol Use Disorder: Targeting the Dark Side
- 25 November 2018
- Published by Springer Nature
- p. 213-220
Anticonvulsants to Treat Cannabis Use Disorder
- 25 November 2018
- Published by Springer Nature
- p. 213-220
Anticonvulsants to Treat Cannabis Use Disorder
- 23 December 2017
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 27 (1) , 113-124
Gabapentin for the treatment of alcohol use disorder
Introduction: Alcohol misuse is the fifth leading risk factor for premature death and disability worldwide. Fewer than 10% of afflicted Americans receive pharmacological treatment for alcohol use disorder. Gabapentin is a calcium channel GABAergic modulator that is widely used for pain. Studies showing reduced drinking and decreased craving and alcohol-related disturbances in sleep and affect in the months following alcohol cessation suggest therapeutic potential for alcohol use disorder. Areas covered: Human laboratory and clinical studies assessing gabapentin for alcohol use disorder are reviewed. Data were obtained by searching for English peer-reviewed articles on PubMed, reference lists of identified articles, and trials registered on clinicaltrials.gov. Additionally, the mechanism of action of gabapentin specific to alcohol use disorder, and studies of gabapentin for alcohol withdrawal and non-alcohol substance use disorders are summarized. Expert opinion: Alcohol use disorder represents a challenge and large, unmet medical need. Evidence from single-site studies lend support to the safety and efficacy of gabapentin as a novel treatment for alcohol use disorder, with unique benefits for alcohol-related insomnia and negative affect, relative to available treatments. Proprietary gabapentin delivery systems may open a path to pivotal trials and registration of gabapentin as a novel treatment for alcohol use disorder.
- 23 December 2017
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 27 (1) , 113-124
Gabapentin for the treatment of alcohol use disorder
Introduction: Alcohol misuse is the fifth leading risk factor for premature death and disability worldwide. Fewer than 10% of afflicted Americans receive pharmacological treatment for alcohol use disorder. Gabapentin is a calcium channel GABAergic modulator that is widely used for pain. Studies showing reduced drinking and decreased craving and alcohol-related disturbances in sleep and affect in the months following alcohol cessation suggest therapeutic potential for alcohol use disorder. Areas covered: Human laboratory and clinical studies assessing gabapentin for alcohol use disorder are reviewed. Data were obtained by searching for English peer-reviewed articles on PubMed, reference lists of identified articles, and trials registered on clinicaltrials.gov. Additionally, the mechanism of action of gabapentin specific to alcohol use disorder, and studies of gabapentin for alcohol withdrawal and non-alcohol substance use disorders are summarized. Expert opinion: Alcohol use disorder represents a challenge and large, unmet medical need. Evidence from single-site studies lend support to the safety and efficacy of gabapentin as a novel treatment for alcohol use disorder, with unique benefits for alcohol-related insomnia and negative affect, relative to available treatments. Proprietary gabapentin delivery systems may open a path to pivotal trials and registration of gabapentin as a novel treatment for alcohol use disorder.
- 1 August 2017
- Published by Elsevier in Neuropharmacology
- Vol. 122, 244-253
Emerging pharmacotherapies for alcohol use disorder
- 1 August 2017
- Published by Elsevier in Neuropharmacology
- Vol. 122, 244-253
Emerging pharmacotherapies for alcohol use disorder
- 6 January 2016
- Published by Annual Reviews in Annual Review of Pharmacology and Toxicology
- Vol. 56 (1) , 299-322
Existing and Future Drugs for the Treatment of the Dark Side of Addiction
The identification of a heuristic framework for the stages of the addiction cycle that are linked to neurocircuitry changes in pathophysiology includes the binge/intoxication stage, the withdrawal/negative affect stage, and the preoccupation/anticipation (craving) stage, which represent neuroadaptations in three neurocircuits (basal ganglia, extended amygdala, and frontal cortex, respectively). The identification of excellent and validated animal models, the development of human laboratory models, and an enormous surge in our understanding of neurocircuitry and neuropharmacological mechanisms have provided a revisionist view of addiction that emphasizes the loss of brain reward function and gain of stress function that drive negative reinforcement (the dark side of addiction) as a key to compulsive drug seeking. Reversing the dark side of addiction not only explains much of the existing successful pharmacotherapies for addiction but also points to vast new opportunities for future medications to alleviate...
- 6 January 2016
- Published by Annual Reviews in Annual Review of Pharmacology and Toxicology
- Vol. 56 (1) , 299-322
Existing and Future Drugs for the Treatment of the Dark Side of Addiction
The identification of a heuristic framework for the stages of the addiction cycle that are linked to neurocircuitry changes in pathophysiology includes the binge/intoxication stage, the withdrawal/negative affect stage, and the preoccupation/anticipation (craving) stage, which represent neuroadaptations in three neurocircuits (basal ganglia, extended amygdala, and frontal cortex, respectively). The identification of excellent and validated animal models, the development of human laboratory models, and an enormous surge in our understanding of neurocircuitry and neuropharmacological mechanisms have provided a revisionist view of addiction that emphasizes the loss of brain reward function and gain of stress function that drive negative reinforcement (the dark side of addiction) as a key to compulsive drug seeking. Reversing the dark side of addiction not only explains much of the existing successful pharmacotherapies for addiction but also points to vast new opportunities for future medications to alleviate...
- Top Cited Papers
- 29 June 2015
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 125 (8) , 3193-3197
Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals
Alcoholism, or alcohol use disorder, is a major public health concern that is a considerable risk factor for morbidity and disability; therefore, effective treatments are urgently needed. Here, we demonstrated that the glucocorticoid receptor (GR) antagonist mifepristone reduces alcohol intake in alcohol-dependent rats but not in nondependent animals. Both systemic delivery and direct administration into the central nucleus of the amygdala, a critical stress-related brain region, were sufficient to reduce alcohol consumption in dependent animals. We also tested the use of mifepristone in 56 alcohol-dependent human subjects as part of a double-blind clinical and laboratory-based study. Relative to placebo, individuals who received mifepristone (600 mg daily taken orally for 1 week) exhibited a substantial reduction in alcohol-cued craving in the laboratory, and naturalistic measures revealed reduced alcohol consumption during the 1-week treatment phase and 1-week post-treatment phase in mifepristone-treated individuals. Mifepristone was well tolerated and improved liver-function markers. Together, these results support further exploration of GR antagonism via mifepristone as a therapeutic strategy for alcoholism.
- 29 June 2015
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 125 (8) , 3193-3197
Top Cited PapersGlucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals
Alcoholism, or alcohol use disorder, is a major public health concern that is a considerable risk factor for morbidity and disability; therefore, effective treatments are urgently needed. Here, we demonstrated that the glucocorticoid receptor (GR) antagonist mifepristone reduces alcohol intake in alcohol-dependent rats but not in nondependent animals. Both systemic delivery and direct administration into the central nucleus of the amygdala, a critical stress-related brain region, were sufficient to reduce alcohol consumption in dependent animals. We also tested the use of mifepristone in 56 alcohol-dependent human subjects as part of a double-blind clinical and laboratory-based study. Relative to placebo, individuals who received mifepristone (600 mg daily taken orally for 1 week) exhibited a substantial reduction in alcohol-cued craving in the laboratory, and naturalistic measures revealed reduced alcohol consumption during the 1-week treatment phase and 1-week post-treatment phase in mifepristone-treated individuals. Mifepristone was well tolerated and improved liver-function markers. Together, these results support further exploration of GR antagonism via mifepristone as a therapeutic strategy for alcoholism.
- 25 February 2015
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 76 (2) , e224-e225
Acamprosate, Alcoholism, and Abstinence
- 25 February 2015
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 76 (2) , e224-e225
Acamprosate, Alcoholism, and Abstinence
- 16 July 2014
- Published by Springer Nature
- p. 1-5
Acamprosate